Neural redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic neuropathy

Medical Science Monitor

Volumn 10, Issue 12, 2004, Pages

  Hayden, Melvin R ^a   Tyagi, Suresh C ^b  

^a University of Missouri   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Atheroscleropathy; Atherosclerosis; Diabetic neuropathy; Endothelial nitric oxide eNO; Endothelial nitric oxide synthase eNOS; Extracellular matrix; Insulin resistance; Oxidative stress; Polyneuropathy; Prediabetes; Reactive oxygen species

Indexed keywords

GLUCOSE; REACTIVE OXYGEN METABOLITE;

CLINICAL PROTOCOL; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; ECONOMIC EVALUATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIMB AMPUTATION; METABOLIC SYNDROME X; MORBIDITY; MULTIPLE ORGAN FAILURE; NERVE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PAIN; PATHOPHYSIOLOGY; REVIEW; RISK REDUCTION; SYMPTOM;

DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; EXTRACELLULAR MATRIX; HUMANS; METABOLIC SYNDROME X; NEURONS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 13944259014     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (184)

1. Simmons Z, Feldman EL: Update on diabetic neuropathy. Curr Opin Neurol, 2002; 15: 595-603
2. Dyck PJ, Kratz KM, Karnes JL et al: The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population based cohort: the Rochester diabetic neuropathy study. Neurology, 1993; 43: 817-24
3. Oberley LW: Free radical and diabetes. Free Radic Bio Med, 1988; 5: 113-24
4. Reaven G: Metabolic Syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation, 2002; 106: 286-88
5. Alberti KGM, Zimmet PZ: For the WHO Consultation: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med, 1998; 15: 539-53
6. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: Findings from the third national health and nutrition examination survey. JAMA, 2002; 287(3): 356-59
7. Jones LC, Clark A: Beta cell neogenesis in type 2 diabetes mellitus. Diabetes, 2001; 50(Suppl.1): S186-S187
8. Guiot Y, Sempoux C, Moulin P, Rahier J: No decrease of the beta cell mass in type 2 patients. Diabetes, 2001; 50(Suppl.1): S188
9. Hayden MR, Tyagi SC: Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome and amylin derived islet amyloid in type 2 diabetes mellitus. JOP. J Pancreas (online), 2002; 3(4): 86-108
10. Hayden MR, Tyagi SC: Intimal Redox Stress: Accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovascular Diabetology, 2002; 1(1): 3
11. Hayden MR, Tyagi SC: Myocardial redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and congestive heart failure. Med Sci Monit, 2003; 9(7): SR35-SR52
12. Hayden MR, Tyagi SC: Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovasc Diabetol, 2004; 3(1): 1
13. Hayden MR Tyagi SC: Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: The pleiotropic effects of folate supplementation. Nutr J, 2004; 3(1): 4
14. Hayden MR, Tyagi SC: Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle Nutrition & Metabolism, 2004; 1: 10
15. Reaven GM: Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes, 1988; 37: 1595-607
16. Tahmasebi M, Puddefoot JR, Inwang ER, Vinson GP: The tissue renin-angiotensin system in human pancreas. J Endocrinol, 1999; 161: 317-22
17. Carlsson PO: The renin-angiotensin system in the endocrine pancreas. JOP. J Pancreas (online), 2001; 2(1): 26-32
18. Ma X, Chapleau MW, Whiteis CA et al: Angiotensin selectively activates a subpopulation of postganglionic sympathetic neurons in mice. Circ Res, 2001; 88(8): 787-93
19. Tham M, Sim MK, Tang FR: Location of renin-angiotensin system components in the hypoglossal nucleus of the rat. Regul Pept, 2001; 101(1-3): 51-57
20. Nickenig G, Roling J, Strehlow K et al: Insulin induces upregulation of vascular AT-1 receptor gene expression by posttranscriptional mechanisms. Circulation, 1998; 98: 2453-60
21. Folli F, Saad MJ, Velloso L et al: Crosstalk between insulin and angiotensin II signaling systems. Exp Clin Endocrinol Diabetes, 1999; 107: 133-39
22. Cooper ME, McNally PG, Phillips PA, Johnston CI: Amylin stimulates plasma renin concentrations in humans. Hypertension, 1995; 26: 460-64
23. Ikeda T, Iwata K, Ochi H: Effect of insulin, proinsulin, and amylin on renin release from perfused rat kidney. Metabolism, 2001; 50: 763-66
24. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res, 2000; 86: 494-501
25. Munzel T, Keaney JF Jr: Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation, 2001; 104: 1571-74
26. Griendling KK, Harrison DG: Out, damned dot: studies of the NADPH oxidase in atherosclerosis. J Clin Invest, 2001; 108: 1423-24
27. Weigert C, Brodbeck K, Klopfer K et al: Angiotensin II induces human TGF-beta 1 promoter activation: similarity to hyperglycaemia. Diabetologia, 2002; 45(6): 890-98
28. Malik RA, Williamson S, Abbott C et al: Effect of angiotensin-converting- enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomized double-blind controlled trial. Lancet, 1998; 353(9145): 1978-81
29. Malik RA: Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibitors? Ann Med, 2000; 32(1): 1-5
30. Reja A, Tesfaye S, Harris ND, Ward JD: Is ACE inhibition with lisinopril helpful in diabetic neuropathy? Diabet Med, 1995; 12(4): 307-9
31. Sugimoto K, Nishizawa Y, Horiuchi S, Yagihashi S: Localization in human diabetic peripheral nerve of N (epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct. Diabetologia, 1997; 40(12): 1389-87
32. Wendt T, Bucciarelli L, Qu W et al: Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep, 2002; 4: 228-37
33. Wendt TM, Bucciarelli LM, Qu WM et al: Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: Insights into the pathogenesis of macrovascular complications in diabetes. Current Atherosclerosis Reports, 2002; 4(3): 228-37
34. Yamamoto Y, Kato I, Doi T et al: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest, 2001; 108(2): 261-68
35. Arai K, Iizuka S, Tada Y et al: Increase in the glycosylated form of erythrocyte CuZnSOD in diabetes and close association of non-enzymatic glycosylation with enzyme activity. Biochim Biophys Acta, 1987; 924: 292-96
36. Jennings PE, Chirico S, Jones AF et al: Vitamin C metabolites and microangiopathy in diabetes mellitus. Diabetes Res, 1987; 6: 151-54
37. Sinclair AJ, Lunec J, Girling AJ, Barnett AH: Modulators of free radical activity in diabetes mellitus: role of ascorbic acid. EXS, 1992; 62: 151-54
38. Giugliano D, Ceriello A, Paolisso G: Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress? Metabolism, 1995; 44: 363-68
39. Duplain H, Burcelin R, Sartori C et al: Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation, 2001; 104: 342-45
40. Miyamoto Y, Saito Y, Kajiyama N et al: Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension, 1998; 32: 3-8
41. Stuhlinger MC, Abbasi F, Chu JW et al: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA, 2002; 287(11): 1420-26
42. Nash DT: Insulin resistance, ADMA levels, and cardiovascular disease. JAMA, 2002; 287(11): 1451-52
43. Christ M, Bauersachs J, Liebetrau C et al: Glucose Increases Endothelial-Dependent Superoxide Formation in Coronary Arteries by NAD(P)H Oxidase Activation: Attenuation by the 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Atorvastatin. Diabetes, 2002; 51(8): 2648-52
44. Stepp DW, Ou J, Ackerman AW et al: Native LDL and minimally oxidized LDL differentially regulate superoxide anion in vascular endothelium in situ. Am J Physiol Heart Circ Physiol, 2002; 283(2): H750-HY759
45. Zou MH, Shi C, Cohen RA: Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest, 2002; 109(6): 817-26
46. Verma S, Wang CH, Li SH et al: A self fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation, 2002; 106(8): 913-19
47. Guzik TJ, Mussa S, Gastaldi D et al: Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation, 2002; 105(14): 1656-62
48. Vasquez-Vivar J, Kalyanaraman B, Martasek P et al: Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA, 1998; 95(16): 9220-25
49. Wong TY, Klein R, Sharrett AR et al: Retinal arteriolar narrowing and risk of diabetes mellitus in middle-aged persons. JAMA, 2002; 287(19): 2528-33
50. Hoffmann J, Haendeler J, Aicher A et al: Aging enhances the sensitivity of endothelial cells toward apoptotic stimuli: important role of nitric oxide. Circ Res, 2001; 89: 709-15
51. Harman D: Extending functional life span. Exp Gerontol, 1998; 33: 95-112
52. Lenaz G: Role of mitochondria in oxidative stress and ageing. Biochim Biophys Acta, 1998; 1366: 53-67
53. Hayden MR, Tyagi SC: Remodeling of the endocrine pancreas: the central role of amylin and insulin resistance. South Med J, 2000; 93(1): 24-28
54. Hayden MR, Tyagi SC: "A" is for amylin and amyloid in type 2 diabetes mellitus. JOP, 2001; 2(4): 124-39
55. Hayden MR: Pancreatic islet amyloid in type 2 diabetes mellitus: a clinical and historical review. Missouri Medicine, 2002; 99(9): 495-98
56. Hayden MR: Islet amyloid, metabolic syndrome, and the natural progressive history of type 2 diabetes mellitus. JOP, 2002; 3(5): 126-38
57. Ye JM, Lim-Fraser M, Cooney GJ et al: Evidence that amylin stimulates lipolysis in vivo: a possible mediator of induced insulin resistance. Am J Physiol Endocrinol Metab, 2001; 280: E562-69
58. Janson J, Ashley RH, Harrison D et al: The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes, 1999; 48: 491-98
59. McGarry JD: Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes, 2002; 51: 7-18
60. Bakker SJ, IJzerman RG, Teerlink T et al: Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclerosis, endothelial dysfunction, and beta cell failure? Atherosclerosis, 2000; 148: 17-21
61. Gotto AM Jr: Triglyceride as a risk factor for coronary artery disease. Am J Cardiol, 1998; 82: 22-25Q
62. Grundy SM: Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol, 1998; 81: 18-25B
63. Lamarche B, Tchernof A, Mauriege P et al: Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA, 1998; 279: 1955-61
64. Williams KJ, Tabas I: The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol, 1995; 15: 551-61
65. Williams KJ, Tabas I: The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol, 1998; 9: 471-74
66. Unger RH, Orci L: Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J, 2001; 15: 312-21
67. Lee Y, Hirose H, Ohneda M et al: Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte beta-cell relationships. Proc Natl Acad Sci USA, 1994; 91: 10878-82
68. Lee Y, Hirose H, Zhou YT et al: Increased lipogenic capacity of the islets of obese rats. A role in the pathogenesis of NIDDM. Diabetes, 1997; 46: 408-13
69. Shimabukuro M, Zhou YT, Levi M, Unger RH: Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA, 1998; 95: 2498-502
70. Shimabukuro M, Higa M, Zhou YT et al: Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyl transferase overexpression. J Biol Chem, 1998; 273(32): 487-90
71. Unger RH: Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes, 1995; 44: 863-70
72. Obeid LM, Linardic CM, Karolak LA, Hannun YA: Programmed cell death induced by ceramide. Science, 1993; 259: 239-47
73. Katsuyama K, Shichiri M, Marumo F, Hirata Y: Role of nuclear factor kappa B activation in cytokine- and sphingomyelinase-stimulated inducible nitric oxide synthase gene expression in vascular smooth muscle cells. Endocrinology, 1998; 139: 4506-12
74. Keane WF, Yukawa S, Mune M: Introduction: State of the art: review of lipids and progressive renal disease. Kidney Int, 1999; 56(S71): 1-2
75. Zethelius B, Byberg L, Hales CN et al: Proinsulin is an independent predictor of coronary heart disease: Report from a 27-year follow-up study. Circulation, 2002; 105(18): 2153-58
76. Yudkin JS, May M, Elwood P et al: Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study. Diabetologia, 2002; 45(3): 327-36
77. Libby P: Atherosclerosis: the new view. Sci Am, 2002; 286(5): 46-55
78. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med, 1999; 340(2): 115-26
79. Pradhan AD, Manson JE, Rifai N et al: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA, 2001; 286(3): 327-34
80. Pradhan AD, Ridker PM: Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J, 2002; 23(11): 831-34
81. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 2000; 342(12): 836-43
82. Ridker PM, Cushman M, Stampfer MJ et al: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med, 1997; 336(14): 973-79
83. Duncan BB, Schmidt MI: Chronic activation of the innate immune system may underlie the metabolic syndrome. Sao Paulo Med J, 2001; 119(3): 122-27
84. Pickup JC, Crook: Is type II diabetes mellitus a disease of the innate immune system? Diabetologia, 1998; 41(10): 1241-48
85. Pickup JC, Mattock MB, Chusney GD, Burt D: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia, 1997; 40(11): 1286-92
86. Yudkin JS, Kumari M, Humpries SE, Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis, 2000; 148: 209-14
87. Wajchenberg BL: Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocrine Reviews, 2000; 21(6): 697-738
88. Lemieux I, Pascot A, Prud'homme D et al: Elevated C-Reactive protein. Another component of the atherothrombotic profile of abdominal obesity. Arteriosclerosis Thrombosis and Vascular Biology, 2001; 21: 961-67
89. Duncan BB, Schmidt MI: Chronic activation of the innate immune system may underlie the metabolic syndrome. Sao Paulo Med J, 2001; 199: 122-27
90. Vozarova B, Weyer C, Lindsay RS et al: High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes, 2002; 51: 455-61
91. Thomas HE, Darwiche R, Corbett JA, Kay TW: Interleukin-1 plus gamma-interferon-induced pancreatic beta-cell dysfunction is mediated by beta-cell nitric oxide production. Diabetes, 2002; 51: 311-16
92. Duncan BB, Schmidt MI, Offenbacher S et al: Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARJC) Study. Diabetes Care, 1999; 22: 767-72
93. Chung HY, Kim HJ, Kim JW, Yu BP: The inflammation hypothesis of aging: molecular modulation by calorie restriction. Ann N Y Acad Sci, 2001; 928: 327-35
94. Pecoits-Filho R, Lindholm B, Stenvinkel P: The malnutrition, inflammation, and atherosclerosis (MIA) syndrome - the heart of the matter. Nephrol Dial Transplant, 2002; 17(S11): 28-31
95. Syed MA, Barinas-Mitchell E, Pietropaolo SL et al: Is type 2 diabetes a chronic inflammatory/autoimmune disease? Diabetes Nutr Metab, 2002; 15(2): 68-83
96. Pietropaolo M, Barinas-Mitchell E, Pietropaolo SL et al: Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. Diabetes, 2000; 49(1): 32-38
97. Zimmet PZ, Tuomi T, Mackay IR et al: Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med, 1994; 11(3): 299-303
98. Litchfield JE, Thorpe SR, Baynes JW: Oxygen is not required for the browning and crosslinking of protein by pentoses: relevance to Maillard reactions in vivo. Int J Biochem Cell Biol, 1999; 31: 1297-305
99. Fu MX, Wells-Knecht KJ, Blackledge JA et al: Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes, 1994; 43: 676-83
100. Hunt JV, Smith CC, Wolff SP: Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes, 1990; 39: 1420-24
101. Williamson JR, Kilo C, Ido Y: The role of cytosolic reductive stress in oxidant formation and diabetic complications. Diabetes Res Clin Pract, 1999; 45: 81-82
102. Ido Y, Kilo C, Williamson JR: Interactions between the sorbitol pathway, non-enzymatic glycation, and diabetic vascular dysfunction. Nephrol Dial Transplant, 1996; 11(Suppl.5): 72-75
103. Williamson JR, Chang K, Frangos M et al: Hyperglycemic Pseudohypoxia and diabetic complications. Diabetes, 1993; 42: 801-13
104. Aronson D, Rayfield EJ: How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol, 2002; 1(1): 1, http:// www.cardiab.com
105. Brodsky SV, Morrishow AM, Dharia N et al: Glucose scavenging of nitric oxide. Am J Physiol Renal Physiol, 2001; 280: F480-86
106. Ihara Y, Toyokuni S, Uchida K et al: Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes, 1999; 48: 927-32
107. Poitout V, Robertson RP: Minireview: Secondary beta-cell failure in type 2 diabetes. A convergence of glucotoxicity and lipotoxicity. Endocrinology, 2002; 143: 339-442
108. Nishikawa T, Edelstein D, Du XL et al: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 2000; 404(6779): 787-90
109. Pennathur S, Wagner JD, Leeuwenburg C et al: A hydroxyl radical-like species oxidizes cynomologus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest, 2001; 107(7): 853-60
110. Berry C, Brosnan MJ, Fennell J et al: Oxidative stress and vascular damage in hypertension. Curr Opin Nephrol Hypertens, 2001; 10: 247-55
111. Kailasam MT, Parmer RJ, Tyrell EA et al: Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk. J Hypertens, 2000; 18: 1611-20
112. Sowers JR: Update on the cardiometabolic syndrome. Clin Cornerstone, 2001; 4: 17-23
113. McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab, 2001; 86: 713-18
114. Jacques PF, Bostom AG, Williams RR et al: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation, 1996; 93: 7-9
115. Arruda VR, von Zuben PM, Chiaparini LC et al: The mutation Ala677->Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost, 1997; 77: 818-21
116. Feix A, Fritsche-Polanz R, Kletzmayr J et al: Increased prevalence of combined MTR and MTHFR genotypes among individuals with severely elevated total homocysteine plasma levels. Am J Kidney Dis, 2001; 38: 956-64
117. Woo KS, Chook P, Lolin YI et al: Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol, 1999; 34: 2002-6
118. Audelin MC, Genest J Jr: Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis, 2001; 159: 497-511
119. Fodinger M, Mannhalter C, Wolfl G et al: Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int, 1997; 52: 517-23
120. Weiss N, Heydrick S, Zhang YY et al: Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine beta-synthase- deficient mice. Arterioscler Thromb Vasc Biol, 2002; 22: 34-41
121. Simon DI, Mullins ME, Jia L et al: Polynitrosylated proteins: characterization, bioactivity and functional consequences. Proc Natl Acad Sci USA, 1996; 93: 4736-41
122. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol, 1996; 271: C1424-37
123. Beckman JS, Beckman TW, Chen J et al: Apparent hydroxy radical production by peroxinitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA, 1990; 87: 1620-24
124. Mujumdar VS, Aru GM, Tyagi SC: Induction of oxidative stress by homocyst(e)ine impairs endothelial function. J Cell Biochem, 2001; 82: 491-500
125. Maejima K, Nakano S, Himeno M et al: Increased basal levels of plasma nitric oxide in Type 2 diabetic subjects. Relationship to microvascular complications. J Diabetes Complications, 2001; 15: 135-43
126. Zhang X, Li H, Jin H et al: Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol, 2000; 279: F671-78
127. Li H, Lewis A, Brodsky S et al: Homocysteine induces 3-hydroxy-3- methylglutaryl coenzyme A reductase in vascular endothelial cells. A mechanism for development of atherosclerosis? Circulation, 2002; 105: 1037-43
128. Stuhlinger MC, Tsao PS, Her JH et al: Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation, 2001; 104(21): 2569-75
129. Kahn SE, Andrikopoulos S, Verchere CB: Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes, 1999; 48: 241-53
130. Wang F, Hull RL, Vidal J et al: Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes, 2001; 50: 2514-20
131. Sandeman DD, Tooke JE: Diabetic vascular disease. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis. London, England: Churchill Livingstone Inc., 1994, 1291-99
132. Hafer-Macko CE, Ivey FM, Gyure KA et al: Thrombomodulin deficiency in human diabetic nerve microvasculature. Diabetes, 2002; 51(6): 1957-63
133. Young MJ, Veves A, Smith JV et al: Restoring lower limb blood flow improves conduction velocity in diabetic patients. Diabetologia, 1995; 38(9): 1051-54
134. Aronson D: Impaired modulation of circadian rhythms in patients with diabetes mellitus: a risk factor for cardiac thrombotic events? Chronobiol Int, 2001; 18(1): 109-21
135. Hansen SH: The role of taurine in diabetes and the development of diabetic complications. Diabetes Metab Res Rev, 2001; 17(5): 330-46
136. Uemura S, Matsushita H, Li W, Glassford AJ et al: Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res, 2001; 88: 1291-98
137. Tyagi SC, Hayden MR: Role of nitric oxide in matrix remodeling in diabetes and heart failure. Heart Failure Reviews, 2003; 8(1): 23-28
138. Sood HS, Hunt MJ, Tyagi SC: Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia. Am J Physiol Lung Cell Mol Physiol, 2003; 284(2): L333-41
139. Camp TM, Tyagi SC, Senior RM et al: Gelatinase B (MMP-9) an apoptotic factor in diabetic transgenic mice. Diabetologia, 2003; [Epub ahead of print]
140. Johnson PJ, Tyagi SC, Katwa LC et al: Activation of extracellular matrix metalloproteinases in equine laminitis. Vet Rec, 1998; 142: 392-96
141. Weber F, Ziegler A: Axonal neuropathy in chronic peripheral arterial occlusive disease. Muscle Nerve, 2002; 26: 471-76
142. McKenzie D, Nukada H, van Rij AM, McMorran PD: Endoneurial microvascular abnormalities of sural nerve in non-diabetic chronic atherosclerotic occlusive disease. J Neurol Sci, 1999; 162(1): 84-88
143. Hayden MR, Tyagi SC: Is type 2 diabetes mellitus a vascular disease (ATHEROSCLEROPATHY) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovascular Diabetology, 2003; 2(1): 2
144. Schratzberger P, Walter DH, Rittig K et al: Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest, 2001; 107(9): 1083-92
145. Simovic D, Ropper AH, Isner JM, Weinberg DH: Improvement in ischemic limb neuropathy after VEGF gene transfer. Circulation, 1999; 18(1): 770
146. Simovic D, Isner JM, Ropper AH et al: Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia. Arch Neurol, 2001; 58(5): 761-68
147. Giannini C, Dyck PJ: Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity. Ann Neurol, 1995; 37(4): 498-504
148. Siperstein MD, Norton W, Unger RH, Madison LL: Muscle capillary basement membrane width in normal, diabetic and prediabetic patients. Trans Assoc Am Physicians, 1966; 79: 330-47
149. Dyck PJ, Hansen S, Karnes J et al: Capillary number and percentage closed in human diabetic sural nerve. Proc Natl Acad Sci USA, 1985; 82(8): 2513-17
150. Dyck PJ, Lais A, Karnes JL et al: Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol, 1986; 19(5): 425-39
151. Dyck PJ, Karnes JL, Daube J et al: Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy. Brain, 1985; 108(Pt 4): 861-80
152. Kilo S, Berghoff M, Hilz M, Freeman R: Neural and endothelial control of the microcirculation in diabetic peripheral neuropathy. Neurology, 2000; 54(6): 1246-52
153. Mooradian AD: Central nervous system complications of diabetes mellitus - a perspective from the blood-brain barrier. Brain Res Brain Res Rev, 1997; 23(3): 210-18
154. Shah GN, Mooradian AD: Age-related changes in the blood-brain barrier. Exp Gerontol, 1997; 32(4-5): 501-19
155. Cucullo L, McAllister MS, Kight K et al: A new dynamic in vitro model for the multidimensional study of astrycyte-endothelial cell interactions at the blood-brain barrier. Brain Res, 2002; 951(2): 243-54
156. Vinik AI: Neuropathy: New concepts in evaluation and treatment. Southern Medical Journal, 2002; 95(1): 21-23
157. Dyck PJ, Windebank AJ: Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve, 2002; 25(4): 477-91
158. Younger DS, Rosoklija G, Hays AP et al: diabetic peripheral neuropathy: a clinicopathologic and immunohistochemical analysis of sural nerve biopsies. Muscle Nerve, 1997; 20(4): 520-21
159. Winer S, Tsui H, Lau A et al: Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive. Nat Med, 2003; 9(2): 198-205
160. Stevens MJ, Feldman EL, Greene DA: The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Diabet Med, 1995; 12(7): 566-79
161. Feldman EL, Stevens MJ, Greene DA: Pathogenesis of diabetic neuropathy. Clin Neurosci, 1997; 4(6): 365-70
162. Sima AA, Cherian PV: Neuropathology of diabetic neuropathy and its correlations with neurophysiology. Clin Neurosci, 1997; 4(6): 359-64
163. Hellweg R, Hartung HD: Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res, 1990; 26(2): 258-67
164. Hansson HA, Bahlin LB, Danielsen N et al: Evidence indicating trophic importance of IGF-1 in regenerating peripheral nerves. Acta Physiol Scand, 1986; 126(4): 609-14
165. Chiarelli F, Santilli F, Mohn A: Role of growth factors in the development of diabetic complications. Horm Res, 2000; 53(2): 53-67
166. Hilz MJ, Marthol H, Neundorfer B: Diabetic somatic polyneuropathy. Pathogenesis, clinical manifestations and therapeutic concepts. Fortschr Neurol Psychiatr, 2000; 68(6): 278-88
167. Zhaung HX, Snyder CK, Pu SF, Ishii DN: Insulin-like growth factors reverse or arrest diabetic neuropathy: effects on hyperalgesia and impaired nerve regeneration in rats. Exp Neurol, 1996; 140(2): 198-205
168. Peirson CR, Zhang W, Murakawa Y, Sima AA: Early gene responses of trophic factors in nerve regeneration differ in experimental type 1 and type 2 diabetic polyneuropathies. J Neuropathol Exp Neurol, 2002; 61(10): 857-71
169. Delaney CL, Russell JW, Cheng HL, Feldman EL: Insulin-like growth factor-1 and over-expression of Bcl-xL prevent glucose-mediated apoptosis in Schwann cells. J Neuropathol Exp Neurol, 2001; 60(2): 147-60
170. Ebendal T: Function and evolution in the NGF family and its receptors. J Neurosci Res, 1992; 32(4): 461-70
171. Faradji V, Sotelo J: Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol Scand, 1990; 81(5): 402-6
172. Thrailkill KM: Insuli-like growth factor-1 in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility. Diabetes Technol Ther, 2000; 2(1): 69-80
173. Grandis M, Nobbio L, Abbruzzese M et al: Insulin treatment enhances expression of IGF-1 in sural nerves of diabetic patients. Muscle Nerve, 2001; 24(5): 622-29
174. Apfel SC: Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol, 2002; 50: 393-413
175. Apfel SC, Schwartz S, Adornato BT et al: Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA, 2000; 84(17): 2215-21
176. Wahren J, Ekberg K, Johansson J et al: Role of C-peptide in human physiology. Am J Physiol Endocrinol Metab, 2000; 278: E759-E768
177. Sima AA, Zhang W, Sugimoto K et al: C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat. Diabetologia, 2001; 44(7): 889-97
178. Ekberg K, Brismar T, Johansson BL et al: Amelioration of sensory nerve dysfunction by C-peptide in patients with type 1 diabetes. Diabetes, 2003; 52(2): 536-41
179. Sima AA: C-peptide and diabetic neuropathy. Expert Opin Investig Drugs, 2003; 12(9): 1471-88
180. Hill RE, Williams PE: A quantitative analysis of perineurial cell basement membrane collagen IV, laminin and fibronectin in diabetic and non-diabetic human sural nerve. Journal of Anatomy, 2002; 201(2): 185-92
181. Kim WK, Kwon SH, Lee SH, Sunwoo IN: Asymptomatic electrophysiologic carpal tunnel syndrome in diabetics: entrapment or polyneuropathy. Yonsei Med J, 2000; 41(1): 123-27
182. Perkins BA, Olaleye D, Bril V: Carpal tunnel syndrome in patients with diabetic polyneuropathy. Diabetes Care, 2002; 25(3): 565-69
183. Hayden MR: Global risk reduction of reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy. Medical Hypotheses and Research, 2004; 1(2/3): 171-85
184. Polydefkis M, Griffin JW, McArthur J: New insights into diabetic polyneuropathy. JAMA, 2003; 290(10): 1371-76